Clinical trials · Illinois
Kidney Diseases clinical trials in Illinois
We’re tracking 39 recruiting kidney diseases studies with a site in Illinois — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT07107945RecruitingPhase 3
Study of empagliflozin for children with chronic kidney disease
This trial tests if empagliflozin, a daily pill, is safe and helps children ages 2–17 with chronic kidney disease (CKD). Your child may be eligible if they have reduced kidney function and elevated protein in their urine, and are already on stable kidney treatments.
Chicago, IllinoisAges 2–17 - NCT06430684RecruitingEarly Phase 1
SGLT2 inhibitor trial for children with kidney disease
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
Chicago, IllinoisAges 12–25 - NCT04334707Recruiting
Study kidney damage in people with long-term diabetes
This study is looking at different kidney health patterns in people with diabetes, especially diabetic kidney disease and people who have not developed kidney damage despite long-term diabetes. It may help researchers understand why kidney problems happen—and what protective factors might prevent them.
Chicago, IllinoisAges 18 years+ - NCT06717698RecruitingPhase 2
Testing a new medicine for kidney damage in chronic kidney disease
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
Skokie, IllinoisAges 18 years+ - NCT07355296RecruitingPhase 2
Testing BI 764198 in adults and teens with kidney disease
This study tests an investigational drug (BI 764198) in adults and teens with different types of kidney disease. The goal is to see if the drug can help slow kidney damage. You may be able to join if your kidney function is at a certain level, you are on stable blood pressure medications, and you haven't had recent strong immune treatments.
Chicago, IllinoisAges 12 years+ - NCT07271186RecruitingPhase 2
Study of a New Drug for Diabetic Kidney Disease
This study tests an investigational drug that blocks a protein called ANGPTL3, which may help protect the kidneys in people with type 2 diabetes and diabetic kidney disease. It aims to see if the drug can reduce kidney damage and improve overall health.
Chicago, IllinoisAges 18–80 - NCT05312879RecruitingPhase 2/Phase 3
Test drug VX-147 for APOL1-related protein in urine kidney disease
This trial studies whether VX-147 can improve kidney disease caused by an APOL1 gene change, which often leads to protein leaking into the urine. It includes both adults and children and focuses on safety and effectiveness over time.
Chicago, IllinoisAges 10–65 - NCT06830629RecruitingPhase 2
MZE829 for APOL1 kidney disease
This trial tests an experimental drug called MZE829 for people with kidney disease linked to the APOL1 gene. It aims to see if the drug can help protect kidney function.
Chicago, IllinoisAges 18–68 - NCT06754280Recruiting
Sitting less for Black adults with chronic kidney disease
This study tests a program to help Black adults with chronic kidney disease sit less and move more throughout the day. You might join if you spend 6 or more hours sitting each day and can walk and stand without help.
Chicago, IllinoisAges 35–80 - NCT06824987RecruitingPhase 2
Study of AZD2373 for APOL1-related kidney disease
This trial tests an experimental drug (AZD2373) for people with kidney disease caused by APOL1 gene changes. It aims to find the safest and most effective dose to slow kidney damage.
Chicago, IllinoisAges 18–65 - NCT06364358Recruiting
Interactive kidney disease education program for African Americans
This study is testing a computer-based education program for African American patients with chronic kidney disease. It aims to help you better understand your condition and treatment options.
Chicago, IllinoisAges 18–70 - NCT07592000RecruitingPhase 1/Phase 2
New Treatment for Type 1 Diabetes With Kidney Disease
This study tests a new experimental medication for people with type 1 diabetes who experience dangerous low blood sugar episodes and have early-stage kidney disease. The trial aims to help improve blood sugar control and reduce these risky episodes.
Chicago, IllinoisAges 18–70 - NCT06902558RecruitingPhase 2
Study of ABBV-CLS-628 for adults with polycystic kidney disease
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
Chicago, IllinoisAges 18–55 - NCT06742723RecruitingPhase 3
Study of baxdrostat and dapagliflozin for kidney disease and high blood pressure
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
Champaign, IllinoisAges 18 years+ - NCT07059962Recruiting
Sensor-based congestion alert for peritoneal dialysis
This study tests a new sensor system that can predict fluid overload (congestion) in people on peritoneal dialysis. It may help you and your care team spot problems early so you can avoid hospital visits.
Chicago, IllinoisAges 21 years+ - NCT07222917RecruitingPhase 2
Dapagliflozin with baxdrostat for kidney disease and high blood pressure
This trial tests if adding dapagliflozin to baxdrostat (a new blood pressure drug) reduces protein in urine better than baxdrostat alone in people with chronic kidney disease and high blood pressure. It aims to find a more effective way to protect kidney health.
Champaign, IllinoisAges 18 years+ - NCT07024823RecruitingPhase 1
Safety study of AZD4248 in healthy people and those with kidney disease and diabetes
This trial tests an experimental drug called AZD4248 to see if it's safe for healthy people and for people with chronic kidney disease and type 2 diabetes. It also checks if a home device can accurately measure kidney function.
Chicago, IllinoisAges 18–75 - NCT06013865RecruitingPhase 4
Empagliflozin for kidney transplant recipients
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
Hines, IllinoisAges 19 years+ - NCT06217302RecruitingPhase 3
Sotagliflozin for kidney protection in type 1 diabetes
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Chicago, IllinoisAges 18–75 - NCT05106387Recruiting
Study follow-up for people who had a kidney transplant
This study follows adults who previously received vonsetamig in an earlier study and then got a kidney transplant while enrolled. It mainly looks at what happens after the transplant and helps doctors understand outcomes over time.
Chicago, IllinoisAges 18–70 - NCT04782258RecruitingPhase 3
Testing the safety of tolvaptan in children with ARPKD
This trial is for children from 28 days old up to 18 years who have a rare kidney disease called ARPKD. It will test if the drug tolvaptan is safe for them. The study helps find new treatment options for kids with this condition.
Chicago, IllinoisAges 4 weeks–18 years - NCT06963827RecruitingPhase 3
Study of mezagitamab for IgA nephropathy
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
Rockford, IllinoisAges 18 years+ - NCT06531824RecruitingPhase 3
Heart and kidney protection study for chronic kidney disease
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
Chicago, IllinoisAges 18 years+ - NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Hinsdale, IllinoisAges 18–75
Kidney Diseases trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting kidney diseases studies listed above.
- Northwestern University · 5 studies
- Research Site · 5 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago · 4 studies
- University of Chicago · 3 studies
- Edward Hines Jr. VA Hospital · 2 studies
- Endeavor Health · 2 studies
- University of Illinois · 2 studies
- Comprehensive Transplant Center
What taking part in a kidney diseases study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Kidney Diseases trials in other states
Common questions
- Are there kidney diseases clinical trials in Illinois?
- Yes. We're currently tracking 39 recruiting kidney diseases studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a kidney diseases study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a kidney diseases trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New kidney diseases studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.